Future Consideration

Timing is everything! If you are passionate about Freenome's mission and want to contribute in a meaningful way, we encourage you to submit your CV or resume. About Freenome Freenome is on a mission to empower everyone with the tools they need to detect, treat, and ultimately prevent diseases. By applying advanced machine learning techniques to recent breakthroughs in genomic science, Freenome is developing simple blood tests to detect early-stage cancer and make treatments more effective. The company has raised $238 million from investors such as RA Capital, Polaris Partners, Perceptive Advisors, Andreessen Horowitz, funds and accounts advised by T. Rowe Price Associates, Inc., GV (formerly Google Ventures), Roche Venture Fund, Kaiser Permanente Ventures, American Cancer Society's BrightEdge Ventures, Data Collective Venture Capital, Novartis and Verily Life Sciences (formerly Google Life Sciences). Our Science Freenome is building technology to gain an understanding of the body through several analytes derived from blood. These signals include cell-free DNA, methylation of cell-free DNA, cell-free RNA, circulating proteins, and immune profiling derived from thousands of prospective samples. By developing novel statistical learning methods and applying them to integrate various -omics datasets, Freenome is a leader in modeling specific biological mechanisms to capture disease dependent signatures such as gene expression, immune response, tumor burden, the tissue of origin, and 3D chromatin structure. By building comprehensive discovery datasets and modeling critical biological systems, Freenome is learning what biological changes are present within the blood between a variety of different disease states including cancer, autoimmune disorders, infections, drug response, and aging. With the combination of Freenome's datasets, cross-functional technical expertise, and mission to uncover the biological truth, we seek to positively change the lives of millions through the early detection and early treatment of disease. Our Culture Freenomers are technical and creative, visionary and grounded, empathetic and passionate. We build teams around divergent expertise, which allows us to solve problems and uncover opportunities in unique ways. Freenomers are some of the most talented experts in their fields, coming together to advance healthcare one breakthrough at a time. We value empathy, integrity, and trust in one another. That means embracing other's perspectives, those of our coworkers and those of the patients and communities we serve. It means knowing when to push, and when to listen. At Freenome, we give each other the benefit of the doubt in the belief that we're all working as a team toward the same goals, and empower others to grow in a collaborative environment.

Freenome is on a mission to empower everyone with the tools they need to detect, treat, and ultimately prevent diseases. By applying advanced machine learning techniques to recent breakthroughs in genomic science, Freenome is developing simple blood tests to detect early-stage cancer and make treatments more effective. The company has raised $238 million from investors such as RA Capital, Polaris Partners, Perceptive Advisors, Andreessen Horowitz, funds and accounts advised by T. Rowe Price Associates, Inc., GV (formerly Google Ventures), Roche Venture Fund, Kaiser Permanente Ventures, American Cancer Society's BrightEdge Ventures, Data Collective Venture Capital, Novartis and Verily Life Sciences (formerly Google Life Sciences).